Success Metrics

Completion Rate
0%(0/1)
Active Trials
0(0%)
Terminated
1(17%)

Phase Distribution

Ph early_phase_1
1
17%
Ph not_applicable
1
17%
Ph phase_2
3
50%
Ph phase_1
1
17%

Phase Distribution

2

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Early Phase 1First-in-human
1(16.7%)
Phase 1Safety & dosage
1(16.7%)
Phase 2Efficacy & side effects
3(50.0%)
N/ANon-phased studies
1(16.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Active(1)
Terminated(1)
Other(4)

Detailed Status

unknown3
Suspended1
Terminated1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
0.0%
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (16.7%)
Phase 11 (16.7%)
Phase 23 (50.0%)
N/A1 (16.7%)

Trials by Status

suspended117%
unknown350%
terminated117%
not_yet_recruiting117%

Recent Activity

0 active trials
Showing 5 of 6
not_yet_recruitingphase_1

"IL-1β Blockade to Prevent Immunothrombosis in Recipients of a Pancreatic Organ"

NCT07503834
suspendedphase_2

Anakinra vs Prednisone to Treat Gout Flare in Patients With Chronic Kidney Disease Stage 4/5 or Renal Transplantation

NCT04844814
unknownphase_2

Efficacy and Safety of Anakinra in Acute Respiratory Distress Syndrome

NCT05914454
unknownnot_applicable

Combination of Inhaled DNase, Baricitinib and Tocilizumab in Severe COVID-19

NCT05279391
unknownearly_phase_1

Pilot Study of the IL-1 Antagonist Anakinra for the Treatment of Endometriosis Related Symptoms

NCT03991520
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT07503834Phase 1

"IL-1β Blockade to Prevent Immunothrombosis in Recipients of a Pancreatic Organ"

Not Yet Recruiting
NCT04844814Phase 2

Anakinra vs Prednisone to Treat Gout Flare in Patients With Chronic Kidney Disease Stage 4/5 or Renal Transplantation

Suspended
NCT05914454Phase 2

Efficacy and Safety of Anakinra in Acute Respiratory Distress Syndrome

Unknown
NCT05279391Not Applicable

Combination of Inhaled DNase, Baricitinib and Tocilizumab in Severe COVID-19

Unknown
NCT03991520Early Phase 1

Pilot Study of the IL-1 Antagonist Anakinra for the Treatment of Endometriosis Related Symptoms

Unknown
NCT04462757Phase 2

SCIL-1Ra in COVID-19 Feasibility & PK/PD

Terminated

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6